Mechanism of action
Antiplatelet agent.
Irreversible P2Y12 receptor antagonists (ADP receptor inhibitor) and hence inhibiting platelet activation and aggregation.
Requires 1 step of bioactivation.
Contraindicated in patients with history of TIA or stroke, and in patients with severe liver failure.
Indications and dose
Side-effects
Bleeding
GI upset
Pruritus
Hypersensitivity (allergy, SJS, TEN, Erythema multidorme)
Thrombotic Thrombocytopenic Purpura
Agranulocytosis
Pharmacokinetics
Onset of action: 30 minutes - 2 hours
Offset of effect: 5-10 days
Excretion: 67% Urine and 28% Feces
Medicinal forms
1 tablet = 5, 10 mg
References
- https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1592/phco.29.9.1089#:~:text=Onset%20of%20antiplatelet%20action%20is,consistent%20than%20that%20with%20clopidogrel.
- https://next.amboss.com/us/article/Um0bUg?q=clopidogrel#Zb288dda860ff65493b01ea10fbf1e10c
- https://online.epocrates.com/drugs/543102/prasugrel/Peds-Dosing
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf
